Health-related quality of life effects of modafinil for treatment of narcolepsy

Kathleen M. Beusterien, Ann E. Rogers, Joyce A. Walsleben, Helene A. Emsellem, Joseph A. Reblando, Lixia Wang, Meeta Goswami, Bruce Steinwald

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Objective: To evaluate the burden of illness of narcolepsy and assess the health-related quality-of-life (HQL) effects of oral modafinil, a wake- promoting therapy for excessive daytime sleepiness associated with narcolepsy. Methods: Subjects with narcolepsy enrolled in a nine-week, placebo-controlled, double-blind study and were randomized to placebo, modafinil 200 mg, or modafinil 400 mg. After the study, consenting subjects received modafinil in a 40-week open-label extension. A self-administered HQL questionnaire consisting of the 36-Item Short Form Health Survey (SF-36) and supplemental narcolepsy-specific scales was given to subjects at baseline, study endpoint, and several open-label timepoints. Results: 481 subjects completed a baseline and double-blind endpoint HQL assessment. Compared to population norms, baseline HQL scores reflected substantial burden in vitality, social functioning, and performing usual activities. At study endpoint, subjects in the 400 mg modafinil group had significantly higher scores than placebo for 10 of the 17 HQL scales. The 400 mg modafinil group had more energy, fewer difficulties performing usual activities, fewer interferences with social activities, improved psychological well-being and higher productivity, attention and self-esteem compared to placebo subjects (p<.05). The positive treatment effects were sustained over the open-label extension. Conclusion: Modafinil significantly improves health-related quality of life in narcolepsy.

Original languageEnglish (US)
Pages (from-to)757-765
Number of pages9
JournalSleep
Volume22
Issue number6
StatePublished - Sep 15 1999

Fingerprint

Narcolepsy
Quality of Life
Placebos
Therapeutics
Cost of Illness
modafinil
Health Surveys
Double-Blind Method
Self Concept
Psychology
Population

Keywords

  • Modafinil
  • Narcolepsy
  • Quality of Life
  • Sf-36

ASJC Scopus subject areas

  • Physiology

Cite this

Beusterien, K. M., Rogers, A. E., Walsleben, J. A., Emsellem, H. A., Reblando, J. A., Wang, L., ... Steinwald, B. (1999). Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep, 22(6), 757-765.

Health-related quality of life effects of modafinil for treatment of narcolepsy. / Beusterien, Kathleen M.; Rogers, Ann E.; Walsleben, Joyce A.; Emsellem, Helene A.; Reblando, Joseph A.; Wang, Lixia; Goswami, Meeta; Steinwald, Bruce.

In: Sleep, Vol. 22, No. 6, 15.09.1999, p. 757-765.

Research output: Contribution to journalArticle

Beusterien, KM, Rogers, AE, Walsleben, JA, Emsellem, HA, Reblando, JA, Wang, L, Goswami, M & Steinwald, B 1999, 'Health-related quality of life effects of modafinil for treatment of narcolepsy', Sleep, vol. 22, no. 6, pp. 757-765.
Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, Wang L et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999 Sep 15;22(6):757-765.
Beusterien, Kathleen M. ; Rogers, Ann E. ; Walsleben, Joyce A. ; Emsellem, Helene A. ; Reblando, Joseph A. ; Wang, Lixia ; Goswami, Meeta ; Steinwald, Bruce. / Health-related quality of life effects of modafinil for treatment of narcolepsy. In: Sleep. 1999 ; Vol. 22, No. 6. pp. 757-765.
@article{e0776e86e218402d8a31b2193d6666b4,
title = "Health-related quality of life effects of modafinil for treatment of narcolepsy",
abstract = "Objective: To evaluate the burden of illness of narcolepsy and assess the health-related quality-of-life (HQL) effects of oral modafinil, a wake- promoting therapy for excessive daytime sleepiness associated with narcolepsy. Methods: Subjects with narcolepsy enrolled in a nine-week, placebo-controlled, double-blind study and were randomized to placebo, modafinil 200 mg, or modafinil 400 mg. After the study, consenting subjects received modafinil in a 40-week open-label extension. A self-administered HQL questionnaire consisting of the 36-Item Short Form Health Survey (SF-36) and supplemental narcolepsy-specific scales was given to subjects at baseline, study endpoint, and several open-label timepoints. Results: 481 subjects completed a baseline and double-blind endpoint HQL assessment. Compared to population norms, baseline HQL scores reflected substantial burden in vitality, social functioning, and performing usual activities. At study endpoint, subjects in the 400 mg modafinil group had significantly higher scores than placebo for 10 of the 17 HQL scales. The 400 mg modafinil group had more energy, fewer difficulties performing usual activities, fewer interferences with social activities, improved psychological well-being and higher productivity, attention and self-esteem compared to placebo subjects (p<.05). The positive treatment effects were sustained over the open-label extension. Conclusion: Modafinil significantly improves health-related quality of life in narcolepsy.",
keywords = "Modafinil, Narcolepsy, Quality of Life, Sf-36",
author = "Beusterien, {Kathleen M.} and Rogers, {Ann E.} and Walsleben, {Joyce A.} and Emsellem, {Helene A.} and Reblando, {Joseph A.} and Lixia Wang and Meeta Goswami and Bruce Steinwald",
year = "1999",
month = "9",
day = "15",
language = "English (US)",
volume = "22",
pages = "757--765",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "6",

}

TY - JOUR

T1 - Health-related quality of life effects of modafinil for treatment of narcolepsy

AU - Beusterien, Kathleen M.

AU - Rogers, Ann E.

AU - Walsleben, Joyce A.

AU - Emsellem, Helene A.

AU - Reblando, Joseph A.

AU - Wang, Lixia

AU - Goswami, Meeta

AU - Steinwald, Bruce

PY - 1999/9/15

Y1 - 1999/9/15

N2 - Objective: To evaluate the burden of illness of narcolepsy and assess the health-related quality-of-life (HQL) effects of oral modafinil, a wake- promoting therapy for excessive daytime sleepiness associated with narcolepsy. Methods: Subjects with narcolepsy enrolled in a nine-week, placebo-controlled, double-blind study and were randomized to placebo, modafinil 200 mg, or modafinil 400 mg. After the study, consenting subjects received modafinil in a 40-week open-label extension. A self-administered HQL questionnaire consisting of the 36-Item Short Form Health Survey (SF-36) and supplemental narcolepsy-specific scales was given to subjects at baseline, study endpoint, and several open-label timepoints. Results: 481 subjects completed a baseline and double-blind endpoint HQL assessment. Compared to population norms, baseline HQL scores reflected substantial burden in vitality, social functioning, and performing usual activities. At study endpoint, subjects in the 400 mg modafinil group had significantly higher scores than placebo for 10 of the 17 HQL scales. The 400 mg modafinil group had more energy, fewer difficulties performing usual activities, fewer interferences with social activities, improved psychological well-being and higher productivity, attention and self-esteem compared to placebo subjects (p<.05). The positive treatment effects were sustained over the open-label extension. Conclusion: Modafinil significantly improves health-related quality of life in narcolepsy.

AB - Objective: To evaluate the burden of illness of narcolepsy and assess the health-related quality-of-life (HQL) effects of oral modafinil, a wake- promoting therapy for excessive daytime sleepiness associated with narcolepsy. Methods: Subjects with narcolepsy enrolled in a nine-week, placebo-controlled, double-blind study and were randomized to placebo, modafinil 200 mg, or modafinil 400 mg. After the study, consenting subjects received modafinil in a 40-week open-label extension. A self-administered HQL questionnaire consisting of the 36-Item Short Form Health Survey (SF-36) and supplemental narcolepsy-specific scales was given to subjects at baseline, study endpoint, and several open-label timepoints. Results: 481 subjects completed a baseline and double-blind endpoint HQL assessment. Compared to population norms, baseline HQL scores reflected substantial burden in vitality, social functioning, and performing usual activities. At study endpoint, subjects in the 400 mg modafinil group had significantly higher scores than placebo for 10 of the 17 HQL scales. The 400 mg modafinil group had more energy, fewer difficulties performing usual activities, fewer interferences with social activities, improved psychological well-being and higher productivity, attention and self-esteem compared to placebo subjects (p<.05). The positive treatment effects were sustained over the open-label extension. Conclusion: Modafinil significantly improves health-related quality of life in narcolepsy.

KW - Modafinil

KW - Narcolepsy

KW - Quality of Life

KW - Sf-36

UR - http://www.scopus.com/inward/record.url?scp=0033568724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033568724&partnerID=8YFLogxK

M3 - Article

C2 - 10505821

AN - SCOPUS:0033568724

VL - 22

SP - 757

EP - 765

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 6

ER -